Possibilities of intestinal dysfunction treatment in period of convalescence of COVID-19

Abstract

The article presents a clinical example of the treatment of persistent intestinal dysfunction in a patient with a relapse and in the period of COVID-19 convalescence. Differential approaches to the clinical and laboratory diagnosis of gastrointestinal disorders in patients with COVID-19 or SARS-CoV-2 infection and with a high risk of pseudomembranous colitis are considered. The role of bacteriophages in restoring the normal function of the gastrointestinal tract is considered. The total duration of treatment of a patient with a gastrointestinal disorder on the background of relapse and subsequent convalescence of COVID-19 from the moment of treatment was 8 weeks with the active use of anti-inflammatory, sorbing, anticoagulant, antiviral and antibacterial therapy. A significant contribution to the process of clinical improvement was made by the use of intestinal bacteriophage, reducing the risk of pseudomembranous colitis.
Conclusions. COVID-19 is a disease characterized by a multisystem lesion and long-term consequences for immunocompetent organs, including the gastrointestinal tract. This fact forces us to reconsider some aspects of traditional therapy for intestinal dysfunction and provides opportunities for new, less aggressive treatments.